These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31629837)

  • 1. Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.
    Shakir R; Adams R; Cooper R; Downing A; Geh I; Gilbert D; Jacobs C; Jones C; Lorimer C; Namelo WC; Sebag-Montefiore D; Shaw P; Muirhead R
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):329-339. PubMed ID: 31629837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis.
    Dasgupta T; Rothenstein D; Chou JF; Zhang Z; Wright JL; Saltz LB; Temple LK; Paty PB; Weiser MR; Guillem JG; Nash GM; Goodman KA
    Radiother Oncol; 2013 May; 107(2):189-94. PubMed ID: 23692961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
    Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors.
    Kapacee ZA; Susnerwala S; Wise M; Biswas A; Danwata F; Scott N
    Colorectal Dis; 2016 Nov; 18(11):1080-1086. PubMed ID: 27028038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy.
    Bogach J; Fenech D; Chu W; Ashamalla S; Ung Y; Taggar AS; Chan KKW; Earle CC; Wong CS
    Cancer Treat Res Commun; 2021; 26():100287. PubMed ID: 33360327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
    Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
    Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
    Elson JK; Kachnic LA; Kharofa JR
    Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience.
    Khosla D; Kapoor R; Dey T; Kataria V; Singh R; Kumar D; Oinam AS; Gupta R; Rana SS; Shah J; Singh H; Irrinki S; Madan R
    J Gastrointest Cancer; 2024 Jun; 55(2):759-767. PubMed ID: 38236375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of definitive radiation with volumetric modulated arc therapy and concurrent chemotherapy for squamous cell carcinoma of the anus in a regional Australian cancer centre.
    Hsieh MT; Shakespeare TP; Winkley L; Goonetilleke D; Yap SZL; Tahir ARM
    J Med Imaging Radiat Oncol; 2024 Apr; 68(3):325-332. PubMed ID: 38450897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
    Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
    Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-five-year experience with radical chemoradiation for anal cancer.
    Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.